(4-氯苯基)(环丙基)甲胺盐酸盐 | 1185166-47-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氯苯基)(环丙基)甲胺盐酸盐
• 英文名称: (4-chlorophenyl)(cyclopropyl)methylamine hydrochloride
• 英文别名: (4-chlorophenyl)(cyclopropyl)methanamine hydrochloride；(4-chlorophenyl)-cyclopropylmethanamine;hydrochloride
• CAS: 1185166-47-5
• 化学式: C₁₀H₁₂ClN*ClH
• mdl: MFCD10639459
• 分子量: 218.126
• InChiKey: IYHHCTOKERFDLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.54
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (4-氯苯基)(环丙基)甲胺盐酸盐 、 5-methyl-imidazo[5,1-b][1,3,4]thiadiazole-2-carboxylic acid hydrochloride 在 1-丙基磷酸酐 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以73%的产率得到5-methylimidazo[5,1-b][1,3,4]thiadiazole-2-carboxylic acid [(4-chlorophenyl)cyclopropylmethyl]amide
  参考文献：
  名称：

  [EN] IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES
  [FR] DÉRIVÉS D'IMIDAZO-OXYDIAZOLE ET D'IMIDAZO-THIADIAZOLE

  摘要：

  本发明提供了Formula (I)的化合物，用作降低淀粉样蛋白β的药物，用于治疗神经退行性疾病。

  公开号：

  WO2013182274A1

文献信息

• [EN] AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS D'AMINE AGISSANT COMME BLOQUEURS DU CANAL POTASSIUM
  申请人：BIONOMICS LTD

  公开号：WO2012155199A1

  公开（公告）日：2012-11-22

  The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

  本发明涉及一种在细胞中调节钾通道活性的化合物，特别是发现在T细胞中的Kv1.3通道的活性。该发明还涉及利用这些化合物治疗或预防自身免疫和炎症性疾病，包括多发性硬化症，含有这些化合物的药物组合物以及其制备方法。
• IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES
  申请人：Ares Trading S.A.

  公开号：US20150175628A1

  公开（公告）日：2015-06-25

  The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.

  本发明提供了一种公式（I）的化合物，用作淀粉样β降低剂，用于治疗神经退行性疾病。
• Carbocyclic compounds as ROR gamma modulators
  申请人：Glenmark Pharmaceuticals S.A.

  公开号：US10189775B2

  公开（公告）日：2019-01-29

  The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

  本公开涉及式 (I) 的新型碳环化合物及其药学上可接受的盐类，其中 R1、R2、R3、R4、R5、R6、Ra、Rb、n、m 和 p 如本文所定义，它们作为视黄醇相关孤儿受体 gamma t（RORγt）的调节剂具有活性。这些化合物可防止、抑制或抑制 RORγt 的作用，因此可用于治疗 RORγt 介导的疾病、失调、综合症或病症，如疼痛、炎症、慢性阻塞性肺病、哮喘、类风湿性关节炎、结肠炎、多发性硬化症、银屑病、神经退行性疾病和癌症。
• NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS
  申请人：Glenmark Pharmaceuticals S.A.

  公开号：US20180237382A1

  公开（公告）日：2018-08-23

  The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R a , R b , n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
• [EN] IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZO-OXYDIAZOLE ET D'IMIDAZO-THIADIAZOLE
  申请人：ARES TRADING SA

  公开号：WO2013182274A1

  公开（公告）日：2013-12-12

  The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.

  本发明提供了Formula (I)的化合物，用作降低淀粉样蛋白β的药物，用于治疗神经退行性疾病。